Jabil

Canaccord Genuity has advised Jabil (NYSE: JBL) on the acquisition of Pharmaceutics International, Inc (Pii)

Canaccord Genuity is pleased to announce that it has acted as the financial adviser to Jabil (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions, on the acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.

This acquisition will significantly enhance Jabil’s existing Pharmaceutical Solutions offering, which includes the development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps. With the addition of Pii’s leading scientific insights, depth of product knowledge, and capabilities across aseptic filling, lyophilization, and oral solid dose manufacturing, Jabil can meet the clinical and commercial drug manufacturing demands of healthcare customers.

By joining Jabil, Pii gains access to an expanded global infrastructure, cutting-edge automation, and enhanced supply chain efficiencies, enabling even greater responsiveness and innovation for their pharmaceutical partners.